Aptose Biosciences
Yahoo Finance • 2 years ago
Aptose Presents Highlights from Clinical Update
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML Patients Favorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R/R AML Populations TP53MUT CR/CRh = 20%... Full story
Yahoo Finance • 2 years ago
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors t... Full story
Yahoo Finance • 2 years ago
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan... Full story
Yahoo Finance • 2 years ago
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
Aptose Biosciences, Inc. SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated... Full story
Yahoo Finance • 2 years ago
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
•AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial •New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient •Aptose Elucidates Rationale for Tuspetinib’s Superior Safety Profile SAN DIEGO and... Full story
Yahoo Finance • 2 years ago
Aptose Reports Results for the Third Quarter 2022
─ Tuspetinib (HM43239) Dose Escalation and Exploration Phase 1/2 Trial in r/r AML Complete; Continued Superior Safety Profile and Clinical Responses Including Complete Remissions as Single Agent Across Three Dose Levels ─ ─ Recruitment Op... Full story
Yahoo Finance • 2 years ago
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignan... Full story
Yahoo Finance • 2 years ago
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
Aptose Biosciences, Inc. SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to tre... Full story
Yahoo Finance • 3 years ago
Aptose Reports Results for the First Quarter 2022
Aptose Biosciences, Inc. Expands HM43239 dose cohort at 160 mg Headway with luxeptinib “G3” formulation in patients Conference call and webcast at 5:00 pm ET today SAN DIEGO and TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- Aptose Bioscien... Full story
